A Trace ‘Tides Primer: Understanding Long Arg3 insulin like growth factor 1

By: Laura Mildon

IGF-1 LR3 is an engineered analogue of insulin-like growth factor 1, or IGF-1. It contains 83 amino acids and is commonly called Long [Arg3]-IGF-I in published research. Its length and folded structure mean it can also be described as a small protein, rather than only a short peptide.

Researchers use it to investigate growth-factor signaling and the influence of IGF-binding proteins. This article explains its identity and selected research without treating laboratory activity as evidence of a benefit for a commercial research material.

What the name means

Natural mature human IGF-1 contains 70 amino acids. The “Long” component refers to a 13-amino-acid extension at the amino-terminal end. “Arg3” means that arginine replaces glutamic acid at position 3 of the original IGF-1 sequence. That numbering refers to the IGF-1 portion, not position 3 of the complete extended chain.

The added sequence is MFPAMPLSSLFVN. Together, the extension and substitution distinguish LR3 from native IGF-1. The analogue is not a naturally occurring version of the hormone.

Chemical identity

The formula is calculated from the published 83-residue sequence with free termini and three disulfide bonds, excluding counterions and water. The reduced chain has six additional hydrogen atoms. The complete sequence and terminal chemistry must be specified when identifying a material. A registry identifier does not establish regulatory approval or verify the identity, purity, or correct folding of a supplied product.

FDA substance identity record and registry disclaimer

Sequence specification from Cayman Chemical

History and research origins

In 1992, Francis and colleagues at an Australian research collaboration reported recombinant IGF-I fusion analogues, including Long [Arg3]-IGF-I. They produced the proteins using an engineered bacterial expression system and investigated folding, binding, and biological activity.

Recombinant production uses genetic instructions introduced into a host cell to make a specified protein. The 1992 publication provides a verifiable development milestone, rather than proof of an exact first-synthesis date.

Selected published research

IGF-1 LR3 is not FDA-approved as a medicine. These studies describe defined laboratory and preclinical findings, rather than clinical effectiveness of a research product.

Binding proteins and cellular activity in 1992

Francis and colleagues compared Long IGF-I analogues with native IGF-I in several cultured cell systems. Their results linked differences in activity to interactions with IGF-binding proteins.

A useful limit appeared in chicken embryo fibroblasts that did not release detectable IGF-binding proteins: Long [Arg3]-IGF-I was less potent than native IGF-I in that system. The paper therefore does not support describing LR3 as uniformly “stronger” in every biological setting.

Francis and colleagues in Journal of Molecular Endocrinology 1992

Binding protein regulation in 1993

A study in cultured HepG2 human hepatoma cells examined how IGF-I, IGF-II, and analogues including Long R3IGF-I affected production of IGF-binding protein 1. The results supported a role for the type I IGF receptor in regulation of that binding protein.

This study concerns receptor signaling and gene regulation in a cell line. Human-derived laboratory cells do not constitute a human clinical trial, and the findings do not establish a whole-body health outcome.

Original study in Molecular and Cellular Endocrinology 1993

Solution structure and molecular flexibility in 2000

Researchers determined a solution structure of Long [Arg3]-IGF-I using nuclear magnetic resonance, or NMR, and molecular modeling. They described similarities to the IGF-I domain as well as differences near its amino terminus and flexibility in parts of the molecule.

NMR uses magnetic properties of atomic nuclei to investigate molecular structure. This work supplies structural evidence for the specific analogue; it does not establish clinical safety or effectiveness.

Original structure study in Journal of Biological Chemistry 2000

Molecular structure

A formula counts atoms, while a protein structure describes their arrangement and folding. A deposited NMR structure is available as Protein Data Bank entry 3LRI. It represents experimentally informed conformations, rather than one rigid shape that applies under every condition.

View the experimental structure in the Protein Data Bank

Why binding proteins matter

IGF-binding proteins, abbreviated IGFBPs, interact with IGF molecules and influence their availability. They are different from the cell-surface receptors that transmit a signal into a cell.

Early comparative experiments found that LR3 interacted less strongly with IGF-binding proteins than native IGF-1. Its apparent activity depended on the cell system and its binding-protein environment. This does not establish a universal potency multiplier or a predictable duration in people.

Original comparative characterization study 1992

Related names that should not be confused

Native IGF-1, IGF-1 LR3, and truncated IGF-1 analogues have different sequences. Findings about one should not be transferred to another without checking the exact molecule and experimental context.

Mecasermin, the active ingredient in INCRELEX, is recombinant human IGF-1 with the native 70-amino-acid sequence. It is different from the 83-amino-acid LR3 analogue. The regulatory status and clinical evidence for mecasermin do not extend to LR3.

Official INCRELEX label identifying mecasermin

What remains unresolved

The selected studies establish research questions about binding, signaling, and structure. They do not resolve long-term human safety or support claims about muscle development, recovery, body composition, or longevity.

A protein’s sequence alone is also insufficient to authenticate a preparation. Correct folding, disulfide connectivity, impurities, and composition matter. A result involving a characterized reagent does not verify the performance of a different supplier’s material.

Regulatory context

IGF-1 LR3 should not be described as FDA-approved because a related IGF-1 medicine exists. FDA’s substance registry explicitly states that availability of a UNII identifier does not imply regulatory review or approval.

Research labeling likewise does not establish clinical safety, approval, or permission for another intended use. Drug approval applies to a specific product and its evaluated conditions, rather than to every molecule in a related growth-factor family.

FDA approval record for INCRELEX mecasermin

Research and regulatory sources checked October 13, 2026.

DISCLAIMER: These statements are for research purposes only and have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why choose Trace 'Tides? 

Because trust starts with real people, clear answers, and quality you can verify. We have a certified peptide specialist on staff, a phone number that connects you with a real human, and a physical location you can visit by appointment. Call or text us—we’re delighted to answer your questions and address your concerns. We also make checkout straightforward by accepting credit cards, without asking you to use cryptocurrency or connect your bank account to an unfamiliar payment app. And every peptide we sell is tested for purity and endotoxins by licensed U.S. laboratories, so you can choose your research peptides with confidence.